23andMe Holding Co. (ME)

0.4402 -0.0079 (-1.76%) At close: 04:00PM EDT

23andMe Holding Co.

349 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 938 6300
https://www.23andme.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 560

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Anne Wojcicki	Co-Founder, CEO, President & Chair of the Board	65k	N/A	N/A
Mr. Joseph Selsavage	Chief Financial & Accounting Officer	624.49k	N/A	1964
Dr. William G. Richards	Head of Therapeutics Discovery	513.22k	N/A	1961
Mr. Eli Fry	Vice President of Operations	N/A	N/A	N/A
Mr. Guy Chayoun	VP, Interim General Counsel & Corporate Secretary	N/A	N/A	N/A
Ms. Katie Watson	Vice President of Communications	N/A	N/A	1978
Mr. Jonathan Ward	Chief Marketing Officer	N/A	N/A	N/A
Mr. Reza Afkhami M.B.A.	Chief Corporate Development Officer	N/A	N/A	N/A
Ms. Savita Pillai	Vice President of People	N/A	N/A	N/A
Dr. Jennifer Low M.D., Ph.D.	Head of Therapeutics Development	N/A	N/A	1969

Amounts are as of 31 December 2024, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the development of novel therapies; and research and development of programs in various therapeutic areas, such as oncology, immunological and inflammatory diseases, and other disease areas, as well as engages in the out-licensing of intellectual property associated with identified drug targets and expenses related to the discovery and development of therapeutic product candidates. This segment also comprises a therapeutics product portfolio, including 23ME-00610 (P006), a humanized monoclonal antibody that interfere with the ability of CD200R1 to interact with CD200 in cancer cells; GSK6097608, an immuno-oncology program for targeting CD96; and 23ME-01473 is an immuno-oncology antibody program that targets the ULBP6 proteins in the NKG2D pathway. 23andMe Holding Co. was founded in 2006 and is headquartered in South San Francisco, California.

Corporate governance

23andMe Holding Co.’s ISS governance QualityScore as of 1 July 2024 is 10. The pillar scores are Audit: 4; Board: 8; Shareholder rights: 10; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.